Related Experiment Videos

Decitabine and its role in the treatment of hematopoietic malignancies

Elizabeth R Plimack1, Hagop M Kantarjian, Jean-Pierre Issa

  • 1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Leukemia & Lymphoma
|August 19, 2007
PubMed

Insights

Decitabine, a DNA methyltransferase inhibitor, effectively treats hematologic malignancies like MDS by reducing abnormal DNA methylation. Further research explores combinations to overcome resistance and improve patient survival.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • DNA methylation abnormalities contribute to cancer by silencing tumor suppressor genes.
  • Decitabine is an S-phase specific DNA methyltransferase inhibitor with hypomethylating activity.
  • Low-dose decitabine shows increased efficacy in hematopoietic malignancies.

Purpose of the Study:

  • To evaluate the efficacy of decitabine in treating hematologic malignancies.
  • To explore decitabine's role in reducing abnormal DNA methylation.
  • To investigate strategies for overcoming resistance to decitabine therapy.

Main Methods:

  • Clinical trials were conducted in the US and Europe.
  • Decitabine was administered at various doses, with a focus on low-dose regimens.
  • Efficacy was assessed in patients with acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome (MDS).

Main Results:

  • Decitabine demonstrated efficacy in acute myeloid leukemia, chronic myeloid leukemia, and MDS.
  • The drug is approved by the FDA for MDS treatment, offering a new therapeutic option.
  • Low-dose decitabine enhances hypomethylating activity in hematopoietic malignancies.

Conclusions:

  • Decitabine is an effective and well-tolerated treatment for MDS.
  • Despite promising activity, primary and secondary resistance to decitabine remain challenges.
  • Combination therapies, such as with histone deacetylase inhibitors, are under investigation to improve outcomes.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...